The role of epoxyeicosatrienoic acids in the cardiovascular system

British Journal of Clinical Pharmacology

Volumn 80, Issue 1, 2015, Pages 28-44

  Yang, L ^a   Maki Petaja K ^a   Cheriyan, J ^a   McEniery, C ^a   Wilkinson, I B ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

cardiovascular system; epoxyeicosatrienoic acids; soluble epoxide hydrolase inhibitor; vascular tone

Indexed keywords

AR 9281; CARDIOVASCULAR AGENT; EPOXYICOSATRIENOIC ACID; GSK 2256294A; UNCLASSIFIED DRUG; HYDROXYICOSATETRAENOIC ACID;

ARACHIDONIC ACID METABOLISM; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL SURVIVAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; HEART PROTECTION; HUMAN; HYDROXYLATION; HYPERPOLARIZATION; LEUKOCYTE ADHERENCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR FUNCTION; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MOLECULAR TARGETED THERAPY;

EID: 84933051181     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12603     Document Type: Article

References (177)

1. World Health Organization. Major causes of death. Available at http://www.who.int/mediacentre/factsheets/fs310/en/index2.html (last accessed 22 March 2014).
2. British Heart Foundation. Cardiovascular diseases statistics. Available at http://www.bhf.org.uk/heart-health/heart-statistics.aspx (last accessed 22 March 2014).
3. Ross MH, Pawlina W,. Histology: a Text and Atlas. 6th Ed. Baltimore: Wolters Kluwer Lippincott Williams & Wilkins, 2011. Chapter 13, p. 400-30.
4. Furchgott RF, Zawadzki JW,. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
5. Dusting GJ, Moncada S, Vane JR,. Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins 1977; 13: 3-15.
6. Moncada S, Vane JR,. The role of prostacyclin in vascular tissue. Fed Proc 1979; 38: 66-71.
7. Feletou M, Vanhoutte PM,. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988; 93: 515-24.
8. 2+ signals through endothelial TRPV4 channels regulate vascular function. Science 2012; 336: 597-601.
9. Wilkinson IB, Webb DJ,. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001; 52: 631-46.
10. Lind L, Berglund L, Larsson A, Sundstrom J,. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation 2011; 123: 1545-51.
11. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A,. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
12. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA,. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8.
13. Takase B, Hamabe A, Satumura K, Akima T, Uehata A, Matsui T, Ohsuzu F, Ishihara M, Kurita A,. Comparable prognostic value of vasodilator response to acetylcholine in brachial and coronary arteries for predicting long-term cardiovascular events in suspected coronary artery disease. Circ J 2006; 70: 49-56.
14. Fichtlscherer S, Breuer S, Zeiher AM,. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the 'vulnerable' patient. Circulation 2004; 110: 1926-32.
15. Bonetti PO, Lerman LO, Lerman A,. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
16. Vallance P, Collier J, Moncada S,. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
17. Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C,. Role of EDHF in type 2 diabetes-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 295: H1982-8.
18. Dawes M, Sieniawska C, Delves T, Dwivedi R, Chowienczyk PJ, Ritter JM,. Barium reduces resting blood flow and inhibits potassium-induced vasodilation in the human forearm. Circulation 2002; 105: 1323-8.
19. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269-72.
20. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, Takeshita A,. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996; 28: 703-11.
21. Alexander SPH, Mathie A, Peters JA,. Guide to Receptors and Channels (GRAC), 5th ed. Br J Pharmacol 2011; 164: S1-324.
22. Imig JD,. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 2012; 92: 101-30.
23. Wei X, Zhang D, Dou X, Niu N, Huang W, Bai J, Zhang G,. Elevated 14,15-epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2-J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer 2014; 14: 841.
24. Shahabi P, Siest G, Meyer UA, Visvikis-Siest S,. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol Ther 2014; 144: 134-61.
25. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC,. Molecular cloning and expression of CYP2J2, a human cytochrome P-450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996; 271: 3460-8.
26. Ma J, Qu W, Scarborough PE, Tomer KB, Moomaw CR, Maronpot R, Davis LS, Breyer MD, Zeldin DC,. Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P-450 highly expressed in kidney. J Biol Chem 1999; 274: 17777-88.
27. Zeldin DC, Foley J, Boyle JE, Moomaw CR, Tomer KB, Parker C, Steenbergen C, Wu S,. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 1997; 138: 1338-46.
28. Zeldin DC, Foley J, Ma J, Boyle JE, Pascual JM, Moomaw CR, Tomer KB, Steenbergen C, Wu S,. CYP2J subfamily P-450's in the lung: expression, localization, and potential functional significance. Mol Pharmacol 1996; 50: 1111-7.
29. Qu W, Bradbury JA, Tsao CC, Maronpot R, Harry GJ, Parker CE, Davis LS, Breyer MD, Waalkes MP, Falck JR, Chen J, Rosenberg RL, Zeldin DC,. Cytochrome P450 CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain. J Biol Chem 2001; 276: 25467-79.
30. Capdevila JH, Falck JR,. Biochemical and molecular characteristics of the cytochrome P450 arachidonic acid monooxygenase. Prostaglandins Other Lipid Mediat 2000; 62: 271-92.
31. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, VanRollins M,. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol 2001; 280: H2430-40
32. Fulton D, Falck JR, McGiff JC, Carroll MA, Quilley J,. A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. J Lipid Res 1998; 39: 1713-21.
33. Fang X, Weintraub NL, McCaw RB, Hu SM, Harmon SD, Rice JB, Hammock BD, Spector AA,. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 2004; 287: H2412-20.
34. Yang T, Peng R, Guo Y, Shen L, Zhao S, Xu D,. The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins. Lipids Health Dis 2013; 12: 151.
35. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC,. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 1998; 83: 932-9.
36. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, da Costa Goncalves ACh, Huang Y, Luft FC, Gollasch M,. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009; 29: 54-60.
37. Morisseau C, Hammock BD,. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005; 45: 311-33.
38. Newman JW, Morisseau C, Hammock BD,. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 2005; 44: 1-51.
39. Spector AA, Fang X, Snyder GD, Weintraub NL,. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004; 43: 55-90.
40. De Mey JG, Claeys M, Vanhoutte PM,. Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther 1982; 222: 166-73.
41. Singer HA, Peach MJ,. Endothelium-dependent relaxation of rabbit aorta. I. Relaxation stimulated by arachidonic acid. J Pharmacol Exp Ther 1983; 226: 790-5.
42. Pinto A, Abraham NG, Mullane KM,. Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J Pharmacol Exp Ther 1987; 240: 856-63.
43. Singer HA, Peach MJ,. Endothelium-dependent relaxation of rabbit aorta. II. Inhibition of relaxation stimulated by methacholine and A23187 with antagonists of arachidonic acid metabolism. J Pharmacol Exp Ther 1983; 226: 796-801.
44. Hecker M, Bara AT, Bauersachs J, Busse R,. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol (Lond) 1994; 481: 407-14.
45. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA,. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 1997; 81: 258-67.
46. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, Michelakis ED,. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 2003; 107: 769-76.
47. Quilley J, McGiff JC,. Is EDHF an epoxyeicosatrienoic acid? Trends Pharmacol Sci 2000; 21: 121-4.
48. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR,. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996; 7: 2364-70.
49. Liu Y, Zhang J, Yu L, Cao F, Rao J, Li J, Jiang C, Falck JR, Jacobs ER, Zhu D,. A soluble epoxide hydrolase inhibitor-8-HUDE increases pulmonary vasoconstriction through inhibition of K(ATP) channels. Pulm Pharmacol Ther 2012; 25: 69-76.
50. Hillig T, Krustrup P, Fleming I, Osada T, Saltin B, Hellsten Y,. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol (Lond) 2003; 546: 307-14.
51. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA,. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol 2001; 280: H2470-7.
52. Passauer J, Bussemaker E, Lassig G, Pistrosch F, Fauler J, Gross P, Fleming I,. Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin Sci (Lond) 2003; 105: 513-8.
53. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I,. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004; 109: 178-83.
54. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, Salvetti A,. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol 2006; 48: 508-15.
55. Bellien J, Remy-Jouet I, Iacob M, Blot E, Mercier A, Lucas D, Dreano Y, Gutierrez L, Donnadieu N, Thuillez C, Joannides R,. Impaired role of epoxyeicosatrienoic acids in the regulation of basal conduit artery diameter during essential hypertension. Hypertension 2012; 60: 1415-21.
56. Ozkor MA, Murrow JR, Rahman AM, Kavtaradze N, Lin J, Manatunga A, Quyyumi AA,. Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. Circulation 2011; 123: 2244-53.
57. 2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 2005; 97: 908-15.
58. Gauthier KM, Rusch NJ,. Potassium channels and membrane potential in vascular endothelial and smooth muscle cells. In: EDHF 2002, ed, Vanhoutte PM,. London: Taylor & Francis, 2003; 1-12.
59. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R,. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401: 493-7.
60. Campbell WB, Gebremedhin D, Pratt, PF, Harder DR,. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78: 415-23.
61. Zhang DX, Mendoza SA, Bubolz AH, Mizuno A, Ge ZD, Li R, Warltier DC, Suzuki M, Gutterman DD,. Transient receptor potential vanilloid type 4-deficient mice exhibit impaired endothelium-dependent relaxation induced by acetylcholine in vitro and in vivo. Hypertension 2009; 53: 532-8.
62. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B,. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 2003; 424: 434-8.
63. Loot AE, Popp R, Fisslthaler B, Vriens J, Nilius B, Fleming I,. Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res 2008; 80: 445-52.
64. Earley S, Pauyo T, Drapp R, Tavares MJ, Liedtke W, Brayden JE,. TRPV4-dependent dilation of peripheral resistance arteries influences arterial pressure. Am J Physiol Heart Circ Physiol 2009; 297: H1096-102.
65. Popp R, Brandes RP, Ott G, Busse R, Fleming I,. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 2002; 90: 800-6.
66. Chaytor AT, Evans WH, Griffith TM,. Central role of heterocellular gap junctional communication in endothelium-dependent relaxations of rabbit arteries. J Physiol 1998; 508: 561-73.
67. Edwards G, Thollon C, Gardener MJ, Feletou M, Vilaine J, Vanhoutte PM, Weston AH,. Role of gap junctions and EETs in endothelium-dependent hyperpolarization of porcine coronary artery. Br J Pharmacol 2000; 129: 1145-54.
68. Griffith TM, Chaytor AT, Edwards DH,. The obligatory link: role of gap junctional communication in endothelium-dependent smooth muscle hyperpolarization. Pharmacol Res 2004; 49: 551-64.
69. 2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: 2612-8.
70. Saliez J, Bouzin C, Rath G, Ghisdal P, Desjardins F, Rezzani R, Rodella LF, Vriens J, Nilius B, Feron o, Balligand JL, Dessy C,. Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells. Circulation 2008; 117: 1065-74.
71. Kohler R, Heyken WT, Heinau P, Schubert R, Si H, Kacik M, Busch C, Grgic I, Maier T, Hoyer J,. Evidence for a functional role of endothelial transient receptor potential V4 in shear stress-induced vasodilatation. Arterioscler Thromb Vasc Biol 2006; 26: 1495-502.
72. Campbell WB, Holmes BB, Falck JR, Capdevila JH, Gauthier KM,. Adenoviral expression of cytochrome P450 epoxygenase in coronary smooth muscle cells: Regulation of potassium channels by endogenous 14(S),15(R)-EET. Am J Physiol 2006; 290: H64-71.
73. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR,. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996; 7: 2364-70.
74. Snyder GD, Krisna UM, Falck JR, Spector AA,. Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am J Physiol 2002; 283: H1936-42.
75. Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, Campbell WB,. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 2008; 324: 1019-27.
76. Chen Y, Falck JR, Manthati VL, Jat JL, Campbell WB,. 20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor. Biochemistry 2011; 50: 3840-8.
77. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, Hammock BD,. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 2007; 82: 42-9.
78. Li PL, Campbell WB,. Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 1997; 80: 877-84.
79. Hayabuchi Y, Nakaya Y, Matsuoka S, Kuroda Y,. Endothelium-derived hyperpolarizing factor activates Ca2'+'-activated K+ channels in porcine coronary artery smooth muscle cells. J Cardiovasc Pharmacol 1998; 32: 642-9.
80. s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 2001; 276: 15983-9.
81. Wong PYK, Lai PS, Shen SY, Belosludtsev YY, Falck JR,. Post-receptor signal transduction and regulation of 14(R), 15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells. J Lipid Mediat Cell 1997; 16: 155-69.
82. Wong PYK, Lai PS, Falck JR,. Mechanism and signal transduction of 14(R), 15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in Guinea pig monocytes. Prostaglandins Other Lipid Mediat 2000; 62: 321-33.
83. Griffith, TM, Chaytor AT, Edwards DH,. Permissive role of cAMP in the mediation of relaxations initiated by endothelial hyperpolarization. In: EDHF 2002, ed, Vanhoutte PM,. London: Taylor & Francis, 2003; 211-22.
84. Li PL, Chen CL, Bortell R, Campbell WB,. 11,12-Epoxyeicosatrienoic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle. Circ Res 1999; 85: 349-56.
85. Ye D, Zhou W, Lee HC,. Activation of rat mesenteric arterial KATP channels by 11,12-epoxyeicosatrienoic acid. Am J Physiol 2005; 288: H358-64.
86. 2+ channels and contraction in mammalian heart cells. J Physiol 1998; 508: 777-92.
87. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL,. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 1999; 55: 288-95.
88. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, Zeldin DC,. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997; 272: 12551-9.
89. Falck JR, Manna S, Moltz J, Chacos N, Capdevila J,. Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem Biophys Res Commun 1983; 114: 743-9.
90. Zeldin DC, Foley J, Boyle JE, Moomaw CR, Tomer KB, Parker C, Steenbergen C, Wu S,. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 1997; 138: 1338-46.
91. Libby P, Ridker PM, Maseri A,. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
92. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK,. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-9.
93. Fleming I., Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 2007; 82: 60-7.
94. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, Zhang R, Gross GJ, Falck JR, Patel PK, Jacobs ER, Medhora M,. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 2008; 294: H724-35.
95. Yang S, Wei S, Pozzi A, Capdevila JH,. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch Biochem Biophys 2009; 489: 82-91.
96. Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, Medhora M,. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vaculature. Am J Physiol Heart Circ Physiol 2006; 291: H517-31.
97. Panigrahy D, Green ER, Pozzi A, Wang DW, Zeldin DC,. EET signaling in cancer. Cancer Metastasis Rev 2011; 30: 525-40.
98. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, Card JW, Wang J, Zeldin DC, Wang DW,. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res 2007; 67: 6665-74.
99. Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, Wang DW,. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther 2009; 329: 908-18.
100. Schachinger V, Zeiher AM,. Atherosclerosis-associated endothelial dysfunction. Z Kardiol 2000; 89: 70-4.
101. Theken KN, Schuck RN, Edin ML, Tran B, Ellis K, Bass A, Lih FB, Tomer KB, Poloyac SM, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA, Lee CR,. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 2012; 222: 530-6.
102. Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD,. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2005; 288: R188-96.
103. Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR,. Enalapril reverses high fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab 2012; 302: E500-9.
104. Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, Tran B, Steele S, Simmons BP, Lih FB, Tomer KB, Wu MC, Hinderliter AL, Stouffer GA, Zeldin DC, Lee CR,. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis 2013; 227: 442-8.
105. Rahman AM, Murrow JR, Ozkor MA, Kavtaradze N, Lin J, Staercke CD, Hooper WC, Manatunga A, Hayek S, Quyyumi AA,. Endothelium-derived hyperpolarizing factor mediates bradykinin-stimulated tissue plasminogen activator release in humans. J Vasc Res 2014; 51: 200-8.
106. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R,. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001; 19: 44-51.
107. Pass GJ, Becker W, Kluge R, Linnartz K, Plum L, Giesen K, Joost HG,. Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome P450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross population. J Pharmacol Exp Ther 2002; 302: 442-50.
108. Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD,. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol 2005; 288: R188-96.
109. Lam JL, Jiang Y, Zhang T, Zhang EY, Smith BJ,. Expression and functional analysis of hepatic cytochromes P450, nuclear receptors, and membrane transporters in 10- and 25-week-old db/db mice. Drug Metab Dispos 2010; 38: 2252-8.
110. Enriquez A, Leclercq I, Farell GC, Robertson G,. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 1999; 255: 300-6.
111. Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T,. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 1998; 273: 31581-9.
112. Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C, Wang CY, Inscho EW, Hammock BD, Wang MH,. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther 2010; 334: 430-8.
113. Makino A, Ohuchi K, Kamata K,. Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br J Pharmacol 2000; 130: 549-56.
114. Wigg SJ, Tare M, Tonta MA, O'Brien RC, Meredith IT, Parkington HC,. Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. Am J Phyiol Heart Circ Physiol 2001; 281: H232-40.
115. Miller AW, Katakam PV, Ujhelyi MR,. Impaired endothelium-mediated relaxation in coronary arteries from insulin-resistant rats. J Vasc Res 1999; 36: 385-92.
116. Katakam, PVG, Hoenig M, Ujhelyi MR, Miller AW,. Cytochrome P450 activity and endothelial dysfunction in insulin resistance. J Vasc Res 2000; 37: 426-34.
117. Jouihan SA, Zuloaga KL, Zhang W, Shangraw RE, Krasnow SM, Marks DL, Alkayed NJ,. Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus. J Cereb Blood Flow Metab 2013; 33: 1650-6.
118. Shi Y, Ku DD, Man RY, Vanhoutte PM,. Augmented endothelium-derived hyperpolarizing factor-mediated relaxations attenuate endothelial dysfunction in femoral and mesenteric, but not in carotid arteries from type 1 diabetic rats. J Pharmacol Exp Ther 2006; 318: 276-81.
119. Makimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahdenpera S, Syvanne M, Mantysaari M, Summanen P, Bergholm R, Taskinen MR, Yki-Jarvinen H,. Impaired endothelium-dependent vasodilation in type 2 diabetes. Diabetes Care 1999; 22: 973-81.
120. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA,. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 2000; 279: F544-51.
121. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, Zhu Y,. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 2007; 104: 9018-23.
122. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL,. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 24: 992-8.
123. Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA,. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci USA 1990; 87: 5893-7.
124. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC,. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 2008; 51: 1379-85.
125. Bellien J, Iacob M, Remy-Jouet I, Lucas D, Monteil C, Gutierrez L, Vendeville C, Dreano Y, Mercier A, Thuillez C, Joannides R,. Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation 2012; 125: 1266-75.
126. Wei Q, Doris PA, Pollizotto MV, Boerwinkle E, Jacobs DR Jr, Siscovick DS, Fornage M,. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 2007; 190: 26-34.
127. Yang Q, Underwood MJ, Hsin MKY, Liu XC, He GW,. Dysfunction of pulmonary vacular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development. Curr Drug Metab 2008; 9: 661-7.
128. Barbera, JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R,. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 2001; 164: 709-13.
129. Yang Q, Shigemura N, Underwood MJ, Hsin M, Xue HM, Huang Y, He GW, Yu CM,. NO and EDHF pathways in pulmonary arteries and veins are impaired in COPD patients. Vascul Pharmacol 2012; 57: 113-8.
130. Fritscher LG, Post M, Rodrigues MT, Silverman F, Balter M, Chapman KR, Zamel N,. Profile of eicosanoids in breath condensate in asthma and COPD. J Breath Res 2012; 6: 026001.
131. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Newby DE, Macnee W,. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 513-20.
132. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ,. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-65.
133. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ,. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011; 66: 585-90.
134. Ashraf MZ, Reddy MK, Hussain ME, Podrez EA, Fahim M,. Contribution of EDRF and EDHF to restoration of endothelial function following dietary restrictions in hypercholesterolemic rats. Indian J Exp Biol 2007; 45: 505-14.
135. Pfister SL, Falck JR, Campbell WB,. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am J Physiol 1991; 261: H843-52.
136. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC, Liao JK,. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110: 2132-6.
137. Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM, Chen JH,. Synergistic effect of cytochrome P450 epoxygenase CYP2J2∗7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2006; 195: 199-206.
138. Wang CP, Hung WC, Yu TH, Chiu CA, Lu LF, Chung FM, Hung CH, Shin SJ, Chen HJ, Lee YJ,. Genetic variation in the G-50'T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp Clin Endocrinol Diabetes 2010; 118: 346-52.
139. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH,. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005; 111: 63-9.
140. Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, Mo W, Zhou HH,. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004; 348: 57-61.
141. Ma Y, Ni W, Zhu W, Xiong Y, Deng X,. Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population. Blood Press 2011; 20: 166-70.
142. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G,. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-17.
143. Fornage M, Boerwinkle E, Doris P, Jacobs D, Liu K, Wong ND,. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects. The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 2004; 109: 335-9.
144. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC,. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006; 15: 1640-9.
145. Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Muller-Myhsok B, Wichmann HE, Meitinger T, Dichgans M,. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. Stroke 2008; 39: 1593-6.
146. Fava C, Montagnana M, Danese E, Almgren P, Hedblad B, Engstrom G, Berglund G, Minuz P, Melander O,. Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. Pharmacogenet Genomics 2010; 20: 94-103.
147. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E,. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 2005; 14: 2829-37.
148. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF,. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 2003; 64: 482-90.
149. Fang X, Weintraub NL, Stoll LL, Spector AA,. Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells. Hypertension 1999; 34: 1242-6.
150. Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ,. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension 2011; 57: 116-U309.
151. Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD,. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1307-17.
152. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD,. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A 2011; 108: 9038-43.
153. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Lliff JJ, DeBarber AE, Koop DR, Alkayed NJ,. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 2008; 39: 2073-8.
154. Yang W, Holmes BB, Gopal VR, Kishore RV, Sangras B, Yi XY, Falck JR, Campbell WB,. Characterization of 14,15-poxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for the studies of metabolism and ligand binding. J Pharmacol Exp Ther 2007; 321: 1023-31.
155. Dimitropoulou C, West L, Field MB, White RE, Reddy LM, Falck JR, Imig JD,. Protein phosphatase 2A and Ca2'+'-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat 2007; 83: 50-61.
156. Elmarakby AA, Falck JR, Imig JD,. Ether epoxyeicosatrienoic acid (EET) analogs lower blood pressure when administered in-vivo to the spontaneously hypertensive rats. FASEB J 2008; 22 (meeting abstract supplement): 479.44.
157. Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR,. Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front Physiol 2010; 3: 157.
158. Hye Khan M, Pavlov TS, Christain SV, Neckar J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD,. Epoxyeicosatrienoic acid (EET) analog lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond) 2014; 127: 463-74.
159. Bellien J, Joannides R, Richard V, Thuillez C,. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: A promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol Ther 2011; 131: 1-17.
160. Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Fiehn O, Hammock BD, Weiss RH,. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model. J Cardiovasc Pharmacol 2008; 52: 314-23.
161. Wang YX, Cassis LA,. Angiogensin II-induced aortic aneurysms. In: A Handbook of Mouse Models for Cardiovascular Diseases, ed, Xu Q,. Chichester England: Life and Medical Sciences, John Wiley & Sons; 2006: 125-36.
162. Neckář J, Kopkan L, Husková Z, Kolar F, Papousek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Maly J, Netuka I, Ostadal B, Cervenka L,. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci (Lond) 2012; 122: 513-25.
163. Kopkan L, Husková Z, Sporková A, Varcabova S, Honetschlagerova Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, Burgelova M, Vojtiskova A, Kujal P, Vernerova Z, Cervenka L,. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press Res. 2012; 35: 595-607.
164. Gao J, Bellien J, Gomez E, Henry JP, Dautreaux B, Bounoure F, Skiba M, Thuillez C, Richard V,. Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension. J Hypertens 2011; 29: 1128-35.
165. Honetschlagerova Z, Kitada K, Huskova Z, Sporkova A, Kopkan L, Burgelova M, Varcabova S, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerova Z, Cervenka L,. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens 2013; 31: 321-32.
166. Iyer A, Kauter K, Alam MA, Hwang SH, Morisseau C, Hammock BD, Brown L,. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res 2012; 2012: 758614.
167. Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM,. Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor. Am J Physiol Cell Physiol 2012; 303: C278-90.
168. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD,. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 2009; 174: 2086-95.
169. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ,. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 2007; 27: 1931-40.
170. Zhang LN, Vincellette J, Chen D, Gless RD, Anandan SK, Rubanyi GM, Webb HK, MacIntyre DE, Wang YX,. Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. Eur J Pharmacol 2011; 654: 68-74.
171. Chen D, Whitcomb R, MacIntyre E, Tran V, Do ZN, Sabry J, Patel DV, Anandan SK, Gless R, Webb HK,. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase in single- and multiple-dose studies in healthy human subjects. J Clin Pharmacol 2012; 52: 319-28.
172. Wang L, Yang J, Guo L, Uyeminami D, Dong H, Hammock BD, Pinkerton KE,. Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2012; 46: 614-22.
173. Keseru B, Barbosa-Sicard E, Schermuly RT, Tanaka H, Hammock BD, Weissmann N, Fisslthaler B, Fleming I,. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs inhibition. Cardiovasc Res 2010; 85: 232-40.
174. Podolin PL, Bolognese BJ, Foley JF, Long E 3rd, Peck B, Umbrecht S, Zhang X, Zhu P, Schwartz B, Xie W, Quinn C, Qi H, Sweitzer S, Chen S, Galop M, Ding Y, Belyanskaya SL, Israel DI, Morgan BA, Behm DJ, Marino JP Jr, Kurali E, Barnette MS, Mayer RJ, Booth-Genthe CL, Callahan JF,. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat 2013; 104-105: 25-31.
175. Falck JR, Kodela R, Manne R, Atcha KR, Puli N, Dubasi N, Manthati VL, Capdevila JH, Yi XY, Goldman DH, Morisseau C, Hammock BD, Campbell WB,. 14,15-Epoxieicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem 2009; 52: 5069-75.
176. Sodhi K, Inoue K, Gotlinger KH, Canestraro M, Vanella L, Kim DH, Manthati VL, Koduru SR, Falck JR, Schwartzman ML, Abraham NG,. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther 2009; 331: 906-16.
177. Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu JY, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD,. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci USA 2014; 111: 11127-32.